Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.45 |
| ▸ | PDE4A | P27815 | 8/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979730 | 0.94 | LMNA (0.51) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2979438 | 0.87 | POLB (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2981478 | 0.86 | POLB (0.52) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2981396 | 0.83 | LMNA (0.40) | PDE4BLMNAHTTSMN1; SMN2TSHR | |
| SCHEMBL2964920 | 0.81 | POLB (0.54) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2979737 | 0.81 | TSHR (0.50) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL2980274 | 0.80 | POLB (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2980289 | 0.80 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL2972125 | 0.79 | TSHR (0.53) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL2980324 | 0.76 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772258-B2 | Agent for treatment of allergic eye disease | NIKKEN CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | NIKKEN CHEMICALS CO., LTD. | 2008-12-11 | — | — | US | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040220227-A1 | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1410795-A1 | REMEDIES FOR ALLERGIC EYE DISEASES | Nikken Chemicals Company, Limited (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220227-A1 | Remedies for allergic eye diseases | HRH2, HRH1, HRH4 | PDE4B 2290/4885PDE4A 1663/4885PDE4C 2319/4885 |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | HRH4, HRH3, HRH2 | PDE4B 2422/4885PDE4A 2224/4885PDE4C 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.